Rituximab (RTX) as an Alternative to TNF-Alpha Antagonists in Patients with Rheumatoid Arthritis and High Risk of Severe Infections: A Systematic Analysis of the Experience in One Center.
CONCLUSIONS: In this particular high risk population of RA patients, treatment with RTX seems to be an alternative to TNF-alpha-antagonist and has a relatively low rate of recurrent infection.
PMID: 23002410 [PubMed]
Source: Open Rheumatology Journal - Category: Rheumatology Tags: Open Rheumatol J Source Type: research
More News: Arthritis | Bronchitis | Osteomyelitis | Pneumonia | Rheumatoid Arthritis | Rheumatology | Rituxan | Tuberculosis